SCHEMBL31225294

SCHEMBL31225294

COC(=O)[C@]1(Sc2ccc(C)cc2)C[C@H](OC(C)=O)[C@@H](NC(C)=O)[C@H]([C@@H](F)[C@@H](COS(=O)(=O)c2ccc(C)cc2)OC(C)=O)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31225310 0.84 NEU4 (0.32) —
SCHEMBL27390994 0.81 POLB (0.31) —
SCHEMBL31695277 0.81 ABCB1 (0.30) —
SCHEMBL24630168 0.81 ABCB1 (0.30) —
SCHEMBL27390989 0.78 NANP (0.42) —
SCHEMBL31225519 0.77 NEU4 (0.32) —
SCHEMBL24630325 0.76 — —
SCHEMBL24630222 0.76 — —
SCHEMBL31695118 0.75 LMNA (0.31) —
SCHEMBL27391585 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 — — EP disclosed
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 — — US disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 — — WO disclosed
Send feedback